TRx 0037

Drug Profile

TRx 0037

Alternative Names: TRx0037

Latest Information Update: 13 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TauRx Therapeutics
  • Class Antidementias
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 12 Nov 2012 Discontinued - Phase-I for Alzheimer's disease in Singapore (PO)
  • 12 Nov 2012 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)
  • 31 May 2010 TauRx Pharmaceuticals completes a phase I trial in Healthy adult and elderly volunteers [NCT01253499] in Singapore and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top